Pasireotide vs Thymosin Alpha-1
Overview
Pasireotide is primarily a hormonal peptide, while Thymosin Alpha-1 is used for healing & recovery.
This page compares Pasireotide and Thymosin Alpha-1 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | Thymosin Alpha-1 | |
|---|---|---|
| Category | Hormonal | Healing & Recovery |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 1.6-3.2 mg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | twice-weekly |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | Immune enhancement, antiviral properties, chronic infection support, cancer therapy adjunct |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Well-tolerated. Rare: injection site reactions, mild flu-like symptoms |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while Thymosin Alpha-1 falls under Healing & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Pasireotide: FDA-approved. Thymosin Alpha-1: not FDA-approved; treated as a research compound.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). Thymosin Alpha-1 is typically dosed at 1.6-3.2 mg (twice-weekly).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and Thymosin Alpha-1 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and Thymosin Alpha-1?
- Pasireotide is primarily a hormonal peptide, while Thymosin Alpha-1 is used for healing & recovery. Pasireotide is FDA-approved for one or more indications, whereas Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is Thymosin Alpha-1 used for?
- Immune system support.
- Can you take Pasireotide and Thymosin Alpha-1 together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and Thymosin Alpha-1 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or Thymosin Alpha-1 FDA-approved?
- Pasireotide is FDA-approved for one or more indications. Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- Thymosin Alpha-1 — full monograph: mechanism, research, dosing & references